Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by scarlet1967on Mar 02, 2021 6:42pm
126 Views
Post# 32698563

RE:RE:RE:RE:RE:RE:RE:Canaccord ups Price Target to $7

RE:RE:RE:RE:RE:RE:RE:Canaccord ups Price Target to $7Both Nash and Abraham have a success rate below 5 of max 10, tossing the coin has better odds.
They are biased as Abraham stayed put for a while as a curtesy thanks to being awarded the closing of the converts and now due to his new circumstances he can't cover the company and as per Nash he put a $12 price target on the company for a good while hoping to push the SP higher so he could be awarded a financing! It is so stupidly obvious that they are bunch of crooks and anyone following them must be mentally compromised, relying on them to ascribe a fair valuation is silly so common Theratechnologies if you read this it's about time to take your own actions rather than relying on others.
<< Previous
Bullboard Posts
Next >>